The Lancet: COVID-19 vaccine hesitancy decreased over time, though mistrust persists among certain groups, study of over 1 million people in England suggests
Peer-Reviewed Publication
Updates every hour. Last Updated: 13-Jan-2026 06:11 ET (13-Jan-2026 11:11 GMT/UTC)
Findings reveal a general decline in vaccine hesitancy during the 15 months following the COVID-19 vaccine roll-out in 2021-2022, with almost two-thirds of those initially hesitant going on to receive one or more COVID-19 vaccinations.
The most common reasons for original COVID-19 vaccine hesitancy were concerns around vaccine effectiveness and side effects. But people who cited these reasons for hesitancy were more likely to change their minds and subsequently get vaccinated.
In contrast, participants who reported being hesitant because of a generalised anti-vaccine sentiment, a mistrust of vaccine developers, or having a low perceived risk from COVID-19 remained more reluctant to receive a COVID-19 vaccine.
The authors say that public health officials and policymakers need to recognise that certain types of vaccine hesitancy are highly context-specific and may be more readily addressed, while others are more resistant to change.
A multiyear community asthma program on the Navajo Nation increased asthma-related care and awareness among families, even as the COVID-19 pandemic dramatically disrupted health care and school systems. The findings come from a new study led by researchers at National Jewish Health and collaborators at the University of Arizona and several partner institutions, in close partnership with Navajo Nation leaders, schools and health systems.
Cambridge-led study calls for urgent increase in international aid for education to address learning losses and the severe psychological impacts of Gaza war.
Researchers estimate children have lost the equivalent of up to five years of learning since 2020, first due to COVID-19, then war.
Eyewitness accounts gathered for the study also report children’s loss of hope and diminishing faith in values such as peace and human rights.
A Viewpoint published in Genomic Psychiatry examines how Brazil's extraordinary genetic diversity creates unparalleled opportunities for longevity research. Dr. Mayana Zatz and her team describe their longitudinal ongoing study which has collected so far over 160 centenarians, including 20 supercentenarians distributed across multiple Brazilian regions. The cohort includes remarkable cases, such as Sister Inah Canabarro Lucas, who was recognized as the world’s oldest living person until her death at age 116 in April 2025, as well as the world’s oldest living man, aged 113, three supercentenarians who survived COVID-19 before vaccines were available, and families with multiple centenarian siblings. Brazil's centuries of genetic admixture may harbor protective variants invisible in more homogeneous populations.
Public health researchers at Columbia University Mailman School of Public Health used computer modeling to reconstruct how the 2009 H1N1 flu pandemic and the 2020 COVID-19 pandemic unfolded in the U.S. The findings highlight the rapid spread of pandemic respiratory pathogens and the challenges of early outbreak containment. The study, published in the journal Proceedings of the National Academy of Sciences, is the first to comprehensively compare the spatial transmission of the last two respiratory pandemics in the U.S. at the metropolitan scale.
New research led by Mass General Brigham investigators suggests that long COVID is more prevalent in school-aged children and adolescents who experience economic instability and adverse social conditions. The multi-center, observational study found that the risk of long COVID was significantly higher in households that faced food insecurity and challenges such as low social support and high levels of discrimination. Results are published in JAMA Pediatrics.
Long COVID—defined as symptoms persisting ≥ 2 months beyond acute SARS-CoV-2 infection without alternative explanation—now affects an estimated 65 million people worldwide and lacks any approved, evidence-based therapy; the present overview therefore synthesizes current mechanistic insights and catalogs experimental interventions ranging from supervised rehabilitation to antivirals, anticoagulants, anti-inflammatories, nutraceuticals and emerging biologics. Key pathogenic drivers include persistent viral reservoirs, chronic low-grade inflammation with IL-1β/IL-6/TNF-α elevation, micro-clot formation via spike-protein–fibrinogen interactions, auto-immunity, gut dysbiosis and mitochondrial dysfunction. These pathways translate into multi-organ sequelae: endothelial dysfunction, myocarditis, neuro-inflammation, small-fiber neuropathy, ME/CFS-like fatigue, menstrual irregularities, glucose intolerance and renal or hepatic injury.